Literature DB >> 21830633

Oral squamous cell carcinoma, socioeconomic status and history of exposure to alcohol and tobacco.

Bukola F Adeyemi1, Adeola A Olusanya, Jonathan O Lawoyin.   

Abstract

Oral squamous cell carcinoma, traditionally a disease of elderly men with a history of chronic exposure to the carcinogenic effects of tobacco and alcohol, is presently being more frequently diagnosed both in a younger patient population and in those not exposed to these carcinogenic substances. At our center, most patients with oral squamous cell carcinoma are not involved in the use of tobacco or alcoholic beverages and are mainly of a low socioeconomic class. This hospital-based case-control study was designed to assess if the risk of developing intraoral squamous cell carcinoma in Ibadan, Nigeria, was associated with the use of tobacco, alcohol, or socioeconomic status. Medical records of patients with histological diagnosis of squamous cell carcinoma of the oral cavity at the University College Hospital, Ibadan, between January 1990 and December 2008 were analyzed. Only 26% of patients gave a positive history of exposure to tobacco, alcohol, or both; of this number, 20.3% used tobacco, while 18.8% consumed alcohol and 13% used both. Although 24.6% of the cases were of high socioeconomic class, there was no significant difference in the distribution of oral cancer patients in the 2 socioeconomic classes. This study revealed an important deviation from expected amongst the oral squamous cell carcinoma patients diagnosed at Ibadan, thus raising the possibility of a different etiology for oral cancer in our population and the need for research focused on identifying possible risk factors.

Entities:  

Mesh:

Year:  2011        PMID: 21830633     DOI: 10.1016/s0027-9684(15)30364-3

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  9 in total

Review 1.  Review: Head and neck squamous cell carcinoma in sub-Saharan Africa.

Authors:  C E Faggons; C Mabedi; C G Shores; S Gopal
Journal:  Malawi Med J       Date:  2015-09       Impact factor: 0.875

2.  Clinicopathological and immunohistochemical evaluation of oral and oropharyngeal squamous cell carcinoma in Chilean population.

Authors:  César Rivera; Wilfredo A González-Arriagada; Marco Loyola-Brambilla; Oslei Paes de Almeida; Ricardo Della Coletta; Bernardo Venegas
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Cytochrome P450 1A1 Ile462Val polymorphism and oral carcinoma risk: an updated meta-analysis including 1,515 cases and 2,233 controls.

Authors:  Xianlu Zhuo; Houyu Zhao; Aoshuang Chang; Huiping Ye; Yan Zhou; Yufeng Song; Yinghui Tan
Journal:  Tumour Biol       Date:  2012-07-31

4.  A comparative study of the oral hygiene status of smokers and non-smokers in Ibadan, Oyo state.

Authors:  Modupe O Arowojolu; Olufunmilayo I Fawole; Elizabeth B Dosumu; O I Opeodu
Journal:  Niger Med J       Date:  2013-07

5.  Epstein-Barr virus infection and oral squamous cell carcinoma risk: A meta-analysis.

Authors:  Yangyang She; Xiaolin Nong; Min Zhang; Menglin Wang
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

6.  Serum levels of single-carbon metabolism vitamins and homocysteine in head-and-neck squamous cell carcinoma: Preliminary report.

Authors:  Victor Ifeolu Akinmoladun; Olatubosun Ganiyu Arinola
Journal:  Ann Afr Med       Date:  2019 Apr-Jun

7.  Evaluation of Epstein-Barr virus expression in oral squamous cell carcinomas.

Authors:  Saeedeh Khalesi; Laleh Maleki; Farzad Ghapani
Journal:  Dent Res J (Isfahan)       Date:  2022-07-18

8.  CLINICO-PATHOLOGIC REVIEW OF BIOPSIED TONGUE LESIONS IN A NIGERIAN TERTIARY HOSPITAL.

Authors:  T J Lasisi; T A Abimbola
Journal:  Ann Ib Postgrad Med       Date:  2017-12

9.  Lack of association of the cyclin D1 G870A variation with oral carcinoma risk: Evidence from 2,404 subjects.

Authors:  Xian-Lu Zhuo; Jun-Jun Ling; Hou-Yu Zhao; Yan Zhou; Yu-Feng Song; Ying-Hui Tan
Journal:  Exp Ther Med       Date:  2012-07-24       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.